VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

PRIMO 2022 | Advances in precision therapy for ovarian cancer

Don Dizon, FACP, FASCO, MD, Brown University, Providence, RI, describes the latest developments in using precision therapy for ovarian cancer. Access to precision therapy has greatly expanded beyond patients with BRCA mutations, and novel research has suggested maintenance PARP inhibitors can result in durable responses, especially in patients with BRCA-positive ovarian cancer. This interview took place at the 7th Annual Practical Recommendations in Immuno and Molecular Oncology Meeting (PRIMO 2022).

Disclosures

Prof. Dizon reports consulting fees from Clovis, AstraZeneca, and Pfizer; and received clinical trial funding from Bristol Myers and Pfizer.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter